PanoramicaGraficoNotizieSchermataTrader

Morgan Stanley Knock-Out IPN/  DE000MA5ZW16  /

EUWAX
12/11/2024  16:15:33 Var.-0.21 Denaro20:48:04 Lettera20:48:04 Sottostante Prezzo di esercizio Expiration date Tipo di opzione
3.55EUR -5.59% 3.54
Quantità in denaro: 400		 -
Quantità in lettera: -		 Ipsen SA 73.6609 - 31/12/2078 Call
GlobeNewswire 29/08 Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Li...
GlobeNewswire 13/08 Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Antici...
GlobeNewswire 08/08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 30/07 Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
GlobeNewswire 26/07 GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cho...
GlobeNewswire 26/07 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire 25/07 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire 25/07 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire 11/07 Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire 09/07 ImCheck Appoints Stephan Braun as Chief Medical Officer
GlobeNewswire 04/07 HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refract...
GlobeNewswire 02/07 Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
GlobeNewswire 02/07 Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire 17/06 GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Det...
GlobeNewswire 11/06 Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire 10/06 GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primar...
GlobeNewswire 10/06 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire 10/06 C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
GlobeNewswire 07/06 Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire 06/06 Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswire 05/06 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire 30/05 NH TherAguix receives FDA Fast Track designation
GlobeNewswire 29/05 GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
GlobeNewswire 22/05 GENFIT: May 22, 2024 Combined Shareholders Meeting Results
GlobeNewswire 15/05 Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results